Preclinical Partnerships APS offers GLP compliant preclinical testing for medical devices and pharmaceuticals with ISO17025 accreditation and AAALAC status, presenting a strong a potential CRO partner for enterprises seeking validated, rapid preclinical study execution under strict regulatory standards.

Global Award Credibility Past recognition such as the Global 3Rs Award enhances credibility with potential clients prioritizing ethical, reduction-focused research practices, aiding outreach to innovative biomed and device companies aiming for responsible R&D.

Expansion Readiness APS emphasizes tailored processes and rapid study design from quote to implementation, signaling agility to scale for startups and established firms during product pivots, regulatory submissions, or tight development timelines.

Partnering Momentum A notable collaboration with Recombinetics on glioblastoma research demonstrates suitability for high-impact, translational projects, suggesting opportunities to target biotech firms pursuing gene editing or advanced therapies.

Scale-Ready Capabilities With mid-market revenue and a comprehensive service catalog spanning biocompatibility, toxicology, pharmacology, animal models, and pathology, APS can be positioned as a single-source preclinical partner to accelerate multi-discipline programs for mid-size to large clients.